CFTR Modulators Stabilize DeltaF508 Protein for Chloride Efflux
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cystic fibrosis, particularly for patients with the ΔF508 mutation, show limited efficacy in increasing chloride ion conductance and stabilizing the CFTR protein at the cell surface, leading to inadequate lung function improvement and frequent hospitalizations.
Innovation Solution
Administering agents that selectively inhibit the interaction between degradation-prone CFTR and CAL, using small organic compounds or peptides to stabilize CFTR proteins, thereby increasing their cell surface expression and chloride efflux, often in combination with CFTR correctors and potentiators.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (antibiotics, postural drainage, chest percussion) are used to control infection and promote mucus clearance, then infection control is improved, but lung function improvement remains inadequate and frequent hospitalizations are required
Solution Approach 1:
The patent introduces CFTR modulators (correctors and potentiators) as intermediary substances that mediate between the defective CFTR protein and functional chloride channels. These compounds act as molecular intermediaries to restore CFTR function, addressing the underlying cause rather than just treating symptoms, thereby improving lung function while maintaining infection control
Solution Approach 2:
The patent applies parameter changes by modifying the biochemical properties of CFTR through pharmacological intervention. Correctors change the folding and trafficking parameters of ΔF508-CFTR, while potentiators modify channel open probability, thereby transforming the functional parameters of the defective protein to achieve therapeutic effects
2Reliability
If KALYDECO (Ivacaftor) is used as monotherapy to potentiate CFTR channel open probability, then chloride conductance is improved in G551D patients, but efficacy is low in ΔF508 homozygous patients
Solution Approach 1:
The patent segments the therapeutic approach into two distinct functional components: correctors that address the trafficking defect specific to ΔF508 mutation, and potentiators that enhance channel function. This segmentation allows each component to target specific aspects of the disease mechanism, enabling effective treatment across different mutation types when combined
Solution Approach 2:
The patent merges corrector and potentiator therapies into a combination treatment regimen. This merging creates a synergistic effect where correctors restore CFTR to the cell surface and potentiators maximize channel function, thereby achieving broad efficacy across different CFTR mutations including both ΔF508 and G551D
3Quantity of substance
If ΔF508-CFTR is overexpressed to appear at the cell surface, then functional CFTR is increased, but CAL directs lysosomal degradation in a dose-dependent fashion
Solution Approach 1:
The patent introduces corrector compounds as intermediary molecules that mediate between the ER quality control system and ΔF508-CFTR. These correctors act as molecular chaperones that facilitate proper folding and protect CFTR from degradation, enabling stable cell surface expression even at higher quantities
Solution Approach 2:
The patent converts the harmful degradation pathway into a beneficial stabilization mechanism. By using correctors to prevent CAL-mediated lysosomal degradation, the therapy transforms the inherently unstable nature of ΔF508-CFTR into an opportunity for controlled, stable expression at the cell surface through pharmacological protection
Data Source
AI summary
A combination therapy and kit including an agent that inhibit the interaction between CAL and mutant CFTR proteins, in combination with a CFTR corrector, CFTR potentiator, mucolytic, anti-inflammatory agent or a combination thereof are provided as is a method for preventing or treating cystic fibrosis.